CliffBio
small molecule

PYLARIFY TRUVU

PIFLUFOLASTAT F-18

Loss of exclusivityJune 2037latest FDA-listed patent expiry
CompanyAPHELION LLC

Drug detail

Brand namePYLARIFY TRUVU
Active ingredientPIFLUFOLASTAT F-18
Strength1mCi/mL-120mCi/mL
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2026
Marketing statusRX

Listed patents

PatentExpiresType
11851407June 2037substance, product
10947197June 2037substance, product
8778305September 2030substance, product
12070513July 2029substance, product
9861713July 2029substance, product
8487129November 2027substance, product

Regulatory exclusivity

CodeExpires
NCEMay 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.